Altamira Therapeutics' Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed JournalGlobeNewsWire • 07/28/22
Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation CheckpointGlobeNewsWire • 07/25/22
Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer TherapyGlobeNewsWire • 07/19/22
Altamira Therapeutic's RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed JournalAccesswire • 07/12/22
Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and PakistanAccesswire • 06/29/22
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic RhinitisAccesswire • 06/27/22
Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19Accesswire • 06/23/22
Altamira Therapeutics Announces Top-Line Data from AM-125 Phase 2 Study in Acute VertigoAccesswire • 06/13/22
Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid RequirementsAccesswire • 06/09/22
Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal SprayAccesswire • 06/08/22
Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in IndonesiaAccesswire • 05/31/22
Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite StudyAccesswire • 05/20/22
Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment ConferenceAccesswire • 05/19/22
Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North MacedoniaAccesswire • 05/05/22
Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19Accesswire • 04/19/22
Altamira Therapeutics Ltd. (CYTO) CEO Thomas Meyer on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/12/22
Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial ResultsAccesswire • 04/12/22
Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta VariantAccesswire • 04/11/22
Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ETAccesswire • 04/04/22
Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with BentrioAccesswire • 03/15/22